AI assistant
Pacira BioSciences, Inc. — Director's Dealing 2021
May 14, 2021
32125_dirs_2021-05-13_c20fa2cf-e5ea-4b48-a260-08779fa723d1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Pacira BioSciences, Inc. (PCRX)
CIK: 0001396814
Period of Report: 2021-03-24
Reporting Person: STACK DAVID M (Director, CEO and Chairman)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-24 | Common Stock | G | 1080 | $0.00 | Disposed | 97273 | Indirect |
| 2021-05-11 | Common Stock | M | 21250 | $10.81 | Acquired | 97311 | Direct |
| 2021-05-11 | Common Stock | S | 13318 | $60.78 | Disposed | 83993 | Direct |
| 2021-05-11 | Common Stock | S | 7932 | $61.19 | Disposed | 76061 | Direct |
| 2021-05-12 | Common Stock | M | 21250 | $10.81 | Acquired | 97311 | Direct |
| 2021-05-12 | Common Stock | S | 2970 | $60.76 | Disposed | 94341 | Direct |
| 2021-05-12 | Common Stock | S | 14669 | $62.08 | Disposed | 79672 | Direct |
| 2021-05-12 | Common Stock | S | 3611 | $62.41 | Disposed | 76061 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-05-11 | Stock Option (Right to Buy) | $10.81 | M | 21250 | Disposed | 2022-06-05 | Common Stock (21250) | Direct |
| 2021-05-12 | Stock Option (Right to Buy) | $10.81 | M | 21250 | Disposed | 2022-06-05 | Common Stock (21250) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 18596 | Indirect |
| Common Stock | 315 | Indirect |
Footnotes
F1: Mr. Stack and his wife are the owners of each of Three Colleens Investment, LLC and LCK Investment LLC. Mr. Stack is the general partner of Stack Schroon Mohawk FLP.
F2: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.995, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 through 7.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.00 to $61.68, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.33 to $61.31, inclusive.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.355 to $62.35, inclusive.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.355 to $62.595, inclusive.
F8: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and as to the remaining shares in successive equal monthly installments for the subsequent 36 months.